At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
AK104biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Open-label, Multicenter, Phase II Study of AK104 in Patients With Metastatic Nasopharyngeal Carcinoma Who Have Progressed After At Least 2 Prior Lines of Chemotherapy
In Brief
A Phase 2 clinical trial evaluating AK104 for Nasopharyngeal Carcinoma. Completed, enrolled 34 participants across 1 site.
Detailed Summary
This is a single-arm, open-label, multicenter, phase II study to evaluate the anti-tumor activity, PK and immunogenicity of AK104 in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior lines of systemic chemotherapy (of which one of them must be platinum-based chemotherapy).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
CollaboratorsAkeso Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartApr 2020
Primary CompletionMay 2021
Study CompletionMar 2023
TodayJul 2026
First PostedJan 7, 2020
Enrollment StartApr 26, 2020
Primary CompletionMay 15, 2021
Study CompletionMar 9, 2023
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 6.5 years ago
Interventions
AK104biological
Subjects will receive AK104 by intravenous administration